Skip to main content
RAPS Euro Convergence 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Ticketed Event
Ticketed Event
Sponsored Presentation
Sponsored Presentation
Learning Level: Foundational
Learning Level: Foundational
New Exhibitor
New Exhibitor
Networking Event
Networking Event
Enterprise Network Member
Enterprise Network Member
Learning Level: Expert
Learning Level: Expert
Learning Level: Advanced
Learning Level: Advanced
Learning Level: Intermediate
Learning Level: Intermediate
Back

Meriem Bouslouk-Marx, PhD, MSc International Health

German HTA Expert
MBM Future Health, AMNOG Advisory Services

Dr. Meriem Bouslouk-Marx advises on Health Technology Assessment (HTA) and reimbursement in Germany. She has comprehensive experience in the assessment of new pharmaceuticals. When Germany introduced AMNOG, the legislation on the mandatory benefit assessment of new medicines, in 2011, she joined the initial small team in charge of implementing the procedure at Germany’s decision-making HTA body, the Federal Joint Committee (G-BA). In this position, she prepared binding national decisions.
Her main responsibilities included conducting scientific consultations with industry and regulatory authorities on clinical trial design and endpoints, assessing submitted dossiers and drafting G-BA resolutions. A particular focus from the outset was on new orphan drugs.
Equipped with her G-BA expertise, she has been providing her strategic services to clients worldwide for several years.

Disclosure information not submitted.

Presentation(s):